Pharmaceuticals

CellOrigin Biotech Announces Global Strategic Collaboration with Qilu Pharma to Develop "Off-the-Shelf" CAR-iMAC Cell Therapy

HANGZHOU, China, Sept. 26, 2022 /PRNewswire/ -- CellOrigin Biotech (Hangzhou) Co., Ltd. announced it has made a global strategic collaboration agreement with Qilu Pharma to develop, manufacture and commercialize proprietary "off-the-shelf" induced pluripotent stem cell- (iPSC) derived Chimeric An...

2022-09-26 12:31 1293

Everest Medicines Receives Approval of Investigational New Drug Application from China NMPA for EVER001, a Novel BTK Inhibitor in Development for Treatment of Renal Diseases

Advancement highlights Everest's potential in providing first-in-class therapies to global patients with glomerular disease SHANGHAI, Sept. 26, 2022 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focu...

2022-09-26 08:00 2215

111, Inc. Announces Appointment of Independent Financial Advisor and Legal Counsel to the Special Committee

SHANGHAI, Sept. 23, 2022 /PRNewswire/ -- 111, Inc. ( "111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company in China, announced today that the special committee (the "Special Committee"), consisting of three independent directors, Mr.Jian Sun, who is the chairman...

2022-09-23 12:30 1586

RVAC Medicines Initiates First-in-Human Clinical Trials for mRNA COVID-19 Vaccine Candidates

SINGAPORE, Sept. 21, 2022 /PRNewswire/ -- RVAC Medicines Pte. Ltd., a messenger RNA (mRNA) technology platform company incubated by CBC Group in 2021, announced today that a participant has been dosed in a Phase 1, first-in-human study evaluating the company's mRNA-based COVID-19 vaccine candidat...

2022-09-22 10:00 1400

Ascentage Pharma Announces Phase I/II Data of Olverembatinib (HQP1351) Published in the Journal of Hematology & Oncology, Further Validating the Drug's Best-in-Class Potential

SUZHOU, China and ROCKVILLE, Md., Sept. 21, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, announced that the results from a Phase I and Phase II study of ...

2022-09-21 22:49 1378

Charsire's New Drug Aims to Capture Multi-Billion-Dollar Dementia Treatment Market

TAINAN CITY, Taiwan, Sept. 21, 2022 /PRNewswire/ -- Charsire Biotechnology Corp. has successfully developed a revolutionary new drug (BAC) for Alzheimer's disease and vascular dementia using its patented technology of Multi-Glycan Complex and soybeans as raw materials. BAC has completed Phase II ...

2022-09-21 20:00 907

MGC Pharmaceuticals Successfully Developed Herbal-inspired Products for Treatment of Long COVID and COVID-19

LONDON, Sept. 21, 2022 /PRNewswire/ -- MGC Pharmaceuticals Ltd. (LSE: MXC), (ASX: MXC), (OTC: MGCLF), is a European based bio-pharma company, focused on developing and supplying affordable (Accessible) and Ethically Produced Plant Inspired Medicines, is helping to solve the mystery of treating Lo...

2022-09-21 17:13 2881

Mediaseek's Proprietary Neurofeedback Engine "Alpha Switch" and Its Smartphone Application Mentioned in International Journal

- Engine and App Used in Research Paper on Chronic Low Back Pain Treatment at Pain Center of Chiba University Hospital Published in "Scientific Reports" - TOKYO, Sept. 21, 2022 /PRNewswire/ -- Mediaseek, Inc. (hereinafter referred to as "Mediaseek") based inTokyo is pleased to announce that a res...

2022-09-21 14:00 992

Sirnaomics to Present Latest Developments on siRNA Therapeutics for Cancer and GalAhead(TM) Platform Programs at the 2nd Annual Oligonucleotide Therapeutics and Delivery Conference

GAITHERSBURG, Md. and SUZHOU, China, Sept. 20, 2022 /PRNewswire/ -- Sirnaomics Ltd . (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today that it will present the la...

2022-09-20 22:40 2632

Alterity Therapeutics Receives U.S. FDA Approval for Investigational New Drug Application for ATH434 for the Treatment of Multiple System Atrophy

Regulatory Authorization Granted to Proceed with ATH434 Phase 2 Clinical Trial MELBOURNE, Australia and SAN FRANCISCO, Sept. 20, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying tr...

2022-09-20 19:25 1238

Menarini and SciClone Sign Exclusive Licensing Agreement to Develop and Commercialize Vaborem® in China to Treat Antimicrobial Resistant Infections

* Vaborem®, a patented combination of meropenem and vaborbactam, is expected to address the rising prevalence of carbapenem-resistant Klebsiella pneumoniae (CRKP) infections inChina * The deal brings together Melinta's innovation, Menarini's cross-regional expertise in registration and market...

2022-09-20 17:00 1954

WuXi Biologics' Drug Substance and Drug Product Facilities Again Approved by U.S. FDA and EMA

WUXI, China, Sept. 20, 2022 /PRNewswire/ --WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced that its two Drug Substance (DS) facilities and a Drug Product (DP) facility located in Wuxi city received reg...

2022-09-20 10:48 1631

RemeGen Announces Preliminary Results of Phase III Confirmatory Study of Telitacicept for Treatment of Systemic Lupus Erythematosus (SLE) in China

YANTAI, China, Sept. 19, 2022 /PRNewswire/ -- RemeGen Co., Ltd. ("RemeGen" or "the Company") (9995.HK, SHA: 688331), a commercial-stage biotechnology company, recently announced the preliminary results of the Phase III confirmatory study of its proprietary novel fusion protein Telitacicept for th...

2022-09-19 21:00 1476

Hummingbird Bioscience Chief Scientific Officer Jerome Boyd-Kirkup to Present at the 2nd Annual VISTA Virtual Symposium

SINGAPORE, Sept. 19, 2022 /PRNewswire/ -- Hummingbird Bioscience, a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases, today announced thatJerome Boyd-Kirkup, Ph.D., Hummingbird Bioscience's Chief Scientific Offic...

2022-09-19 20:00 1236

Anyong Biotechnology's Locally Sourced 'Santé Silver Perch Essence' Fulfilling Increasing Demand in The APAC Wellness Industry

KAOHSIUNG, Taiwan, Sept. 19, 2022 /PRNewswire/ -- Taiwan-based Anyong Biotechnology, has created a locally-sourced Santé Silver Perch Essence out of ecologically farmed, certified, and traceable silver perch in major markets such asTaiwan, the United States, Singapore, and Malaysia. As consumers'...

2022-09-19 16:30 1728

MagicTouch SCB receives IDE approval for In-Stent Restenosis indication

TAMPA, Fla., Sept. 19, 2022 /PRNewswire/ -- The US FDA has granted an Investigational Device Exemption (IDE) approval forMagicTouch  Sirolimus Coated Balloon (SCB) indicated for In-Stent Restenosis (ISR).

2022-09-19 12:20 1807

Everest Medicines Appoints Rogers Yongqing Luo as Chief Executive Officer to Lead Next Stage of Company Growth

SHANGHAI, Sept. 19, 2022 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products to address critical unmet needs inAsia Pacific ...

2022-09-19 08:00 3971

CellResearch Corporation (CRC) announces positive results of Phase I study for CorLiCyte®

SINGAPORE, Sept. 17, 2022 /PRNewswire/ -- CellResearch Corporation, a Singapore -based biopharmaceutical company today announced it has successfully closed the first Phase I study in CorLiCyte®, a stem cell therapy derived from umbilical cord lining stem cells, with research partners at theUnivers...

2022-09-17 00:20 2327

New treatment for rare cancer cholangiocarcinoma approved in Australia

* Available to treat adults with locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or rearrangement * PEMAZYRE® (pemigatinib) is available via a co-pay access program in Australia SINGAPORE, Sept. 15, 2022 /PRNewswire/ -- A NEW targeted therapy to treat a rare bile duct c...

2022-09-15 21:00 1355

Hexvix®, A Diagnostic Drug of Asieris, is Now Covered by the 2022 Lecheng Global Specialty Drug Insurance

SHANGHAI, Sept. 15, 2022 /PRNewswire/ -- Asieris Pharmaceuticals (688176.SH), a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced today that Hexvix®, a drug used for...

2022-09-15 17:07 1202
1 ... 104105106107108109110 ... 291

Week's Top Stories